Syngene Internatl.

** India's Syngene International SYNN.NS slides 9.4% to six-year low of 375.25 rupees

** Pharmaceutical contract research firm posts 90 million rupees ($941,422.59) loss for Q1, vs profit of 867 million rupees a year ago

** Revenue drops 15.8% year-on-year; co says performance impacted by lower offtake from a major client and forex hedge losses

** Co expects fiscal year 2027 revenue to drop in single-digit in rupee terms and operating margins in mid-20s

** Brokerage ICICI Securities says Q1 performance was below par across all parameters

** Adds that while recent contract extension with global biopharma company Bristol Myers Squibb BMY.N till 2035 is a positive development, poor earnings and prolonged recovery would be a major dampener for investors

** More than 4.1 million shares change hands, ~5x of 30-day average daily volume

** Stock rated "Buy" on average by eight brokerage firms, median PT at 532 rupees, per data compiled by LSEG

** YTD, SYNN down 40%

($1 = 95.6000 Indian rupees)

(Reporting by Vivek Kumar M)

(([email protected];))

Syngene International lowered its full-year revenue guidance to single-digit degrowth in its quarterly investor presentation, retreating from the flat revenue outlook it had issued at the close of the previous financial year. The company also guided for EBITDA margins in the mid-20s for FY27. The revision followed a 16% year-on-year drop in June-quarter revenue to Rs 736 crore, as destocking by a large manufacturing client continued to weigh on performance. Separately, Syngene signed a memorandum of understanding with BRIC-THSTI, a government institute, to establish a joint operational partnership for early- and late-phase clinical development, translational research, and bioanalytical sciences. The guidance cut arrives at the start of new managing director Siddharth Mittal's tenure and ahead of the company's detailed 30 July conference call. Syngene had reported Rs 3,739 crore in revenue for the year to March 2026, with net cash of Rs 1,800 crore at the balance-sheet date.

Powered by Tijori

July 29 (Reuters) - Syngene International Ltd SYNN.NS:

• JUNE-QUARTER CONSOL LOSS 90 MILLION RUPEES

• JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 7.36 BILLION RUPEES

Source text: [ID:]

Further company coverage: SYNN.NS

(([email protected];))

July 7 (Reuters) - Syngene International Ltd SYNN.NS:

• SYNGENE INTERNATIONAL - CO GRANTED TAX REFUND OF 86.2 MILLION RUPEES

Source text: ID:nBSE30cxXB

Further company coverage: SYNN.NS

(([email protected];))

Syngene International appointed Siddharth Mittal as Managing Director and Chief Executive Officer, effective 1 July 2026. He succeeds Peter Bains, who completed his tenure on 30 June 2026. Mittal joins from Biocon Limited, where he most recently served as Managing Director and CEO and, earlier, as Chief Financial Officer. During his thirteen years at Biocon, he played a key role in commercializing the GLP‑1 portfolio, securing regulatory approvals, and driving operational excellence. Syngene's Executive Chairperson Kiran Mazumdar‑Shaw stated that the company is at an inflection point and expressed confidence that Mittal's leadership will unlock long‑term value.

Powered by Tijori

July 1 (Reuters) - Syngene International Ltd SYNN.NS:

• SYNGENE INTERNATIONAL - SIDDHARTH MITTAL APPOINTED AS MD, CEO

Source text: ID:nnAZN4T5G6M

Further company coverage: SYNN.NS

(([email protected];))

April 29 (Reuters) - Syngene International Ltd SYNN.NS:

• INDIA'S SYNGENE INTERNATIONAL MARCH-QUARTER CONSOL PROFIT 1.48 BILLION RUPEES

• SYNGENE INTERNATIONAL MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 10.37 BILLION RUPEES

• DECLARES DIVIDEND OF 1.25 RUPEES PER SHARE

Source text: [ID:]

Further company coverage: SYNN.NS

(([email protected];))

March 27 (Reuters) - Syngene International Ltd SYNN.NS:

• RESIGNATION OF PETER BAINS AS MD & CHIEF EXECUTIVE OFFICER

• APPOINTED SIDDHARTH MITTAL AS ADDITIONAL DIRECTOR, DESIGNATED AS MD& CEO

• CHANGE OF ROLE OF KIRAN MAZUMDAR SHAW, FROM NON-EXEC CHAIRPERSON TO EXEC CHAIRPERSON

Source text: ID:nnAZN4SNOU4

Further company coverage: SYNN.NS

(([email protected];))

Feb 18 (Reuters) - Syngene International Ltd SYNN.NS:

• SYNGENE INTERNATIONAL LTD - PARTIAL RELIEF GRANTED TO COMPANY IN TAX APPEALS

• SYNGENE INTERNATIONAL LTD - COMPANY EXPECTS NO MATERIAL IMPACT ON FINANCIALS

Source text: ID:nNSEbp2h0n

Further company coverage: SYNN.NS

(([email protected];))

** Shares of Syngene International SYNN.NS fall as much as 8.1% to 506 rupees, lowest level since March 2021

** On Friday, co slashed FY26 revenue estimate from above 5% to 3-5%

**Jefferies downgrades stock to "underperform"; PT to 480 rupees from 660 rupees

** Says contract research firm missed revenue, EBITDA estimates; co's guidance was lowered due to destocking challenges; likely to impact FY27 too

** Adds, SYNN lacks a meaningful project pipeline, leading to growth stagnation

** More than 3 mln shares traded so far vs 30 day avg of 717,248 shares

** Stock fell 24.2% in 2025

(Reporting by Mridula Kumar in Bengaluru)

(([email protected];))

** Shares of Syngene International SYNN.NS fall as much as 5.6% to a near three-year low of 559.10 rupees, last down 2.3%
** The contract research firm's Q3 net profit dips ~89% year-on-year to 150 million rupees ($1.6 million); revenue slips 2.8% y/y

** Macquarie says revenue shortfall was primarily driven by lower sales of a key biologics product, reflecting normalisation of quarterly revenue

** Brokerage expects SYNN's earnings growth to continue in FY26, with operational efficiencies and capacity addition at its plants as well as new client additions supporting earnings growth through the year
** Avg rating of 8 analysts is "buy" and median PT is 725 rupees - data compiled by LSEG

** SYNN fell 24.1% in 2025

($1 = 91.6100 Indian rupees)

(Reporting by Brijesh Patel in Bengaluru)

(([email protected]; Ph no. +91 9590227221;))

Jan 22 (Reuters) - Syngene International Ltd SYNN.NS:

• SYNGENE INTERNATIONAL LTD DEC-QUARTER CONSOL PROFIT 150 MILLION RUPEES

• SYNGENE INTERNATIONAL LTD DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 9.17 BILLION RUPEES

Further company coverage: SYNN.NS

(([email protected];))

July 23 (Reuters) - Syngene International Ltd SYNN.NS:

• JUNE-QUARTER CONSOL PROFIT 867 MILLION RUPEES

• JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 8.75 BILLION RUPEES

Source text: ID:nBSE14h1sJ

Further company coverage: SYNN.NS

(([email protected];;))

** Shares of Syngene International SYNN.NS down 12.3% to 656.7 rupees
** The contract research firm's Q4 consol profit fell 2.8% y/y to 1.83 bln rupees ($21.4 mln) on higher tax expenses
** Co's CFO Deepank Jain says co expects EBITDA margin to moderate from current levels to the mid-twenties and year-on-year decline in profit after tax for FY26
** Stock set for sharpest ever intraday pct fall
** More than 13.9 mln shares traded, 21.3x its 30-day moving avg
** Shares changed hands most since its first session of trading on Aug 11, 2015
** Avg rating of 10 analysts is "buy" and median PT is 835 rupees, ~27% higher than current price - data compiled by LSEG
** SYNN extends YTD losses to ~23.5%

($1 = 85.4740 Indian rupees)

(Reporting by Anuran Sadhu in Bengaluru)

(([email protected]; +91 8697274436;))

April 23 (Reuters) - Syngene International Ltd SYNN.NS:

• MARCH-QUARTER CONSOL PROFIT 1.83 BILLION RUPEES

• MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 10.18 BILLION RUPEES

• DIVIDEND OF 1.25 RUPEES PER SHARE

Source text: [ID:]

Further company coverage: SYNN.NS

(([email protected];;))

March 28 (Reuters) - Syngene International Ltd SYNN.NS:

• NATIONAL FACELESS ASSESSMENT CENTRE DROPS PENALTY PROCEEDINGS FOR 33.6 MILLION RUPEES

Source text: ID:nNSE4r4lLF

Further company coverage: SYNN.NS

(([email protected];))

March 26 (Reuters) - Syngene International Ltd SYNN.NS:

• SYNGENE INTERNATIONAL - GETS TAX DEMAND ORDER FOR 2.4 MILLION RUPEES

Source text: ID:nBSEc45f7H

Further company coverage: SYNN.NS

(([email protected];))

Adds details from Emergent's statement in paragraphs 4 & 7, background in paragraphs 5&6

March 10 (Reuters) - India's Syngene International on Monday said it has acquired its first biologics facility in the United States from Emergent Manufacturing Operations Baltimore, a unit of Emergent BioSolutions EBS.N, for $36.5 million.

The contract research firm's acquisition of the facility aligns with broader industry efforts in India to reduce dependence on China by expanding capabilities in other regions.

The Baltimore-Bayview facility, which the contract research firm said is strategically located near key biotech hubs in the Northeast U.S., is expected to be operational for client projects from the second half of 2025.

As part of the agreement, Emergent said it will retain the rights to secure manufacturing services and capacity at the facility in collaboration with Syngene.

Emergent shut the facility last year as part of its ongoing efforts to cut costs and pivot away from contract manufacturing business as a funding crunch forced its smaller biotech clients to cut back on research spending.

Emergent also faced quality issues at the plant during the pandemic while producing Johnson & Johnson's JNJ.N COVID-19 vaccine.

However, the U.S. drugmaker said the U.S. Food and Drug Administration cleared the facility last year and is now in compliance with the required guidelines.

This acquisition, expected to close in March 2025, will boost Syngene's total single-use bioreactor capacity to 50,000 liters from 20,000 liters, enhancing its capabilities in large molecule discovery, development and manufacturing services.

"In the short term, we expect minor dilution of operating margins as a result of costs to be incurred in this facility," Deepak Jain, Syngene International's chief financial officer, said.

India's contract research development and manufacturing organisation sector has the potential to grow seven-fold to $22 billion-$25 billion by 2035, according to a report by Boston Consulting Group.

(Reporting by Yagnoseni Das and Mariam Sunny in Bengaluru; Editing by Vijay Kishore)

(([email protected];))

March 7 (Reuters) - Syngene International Ltd SYNN.NS:

• PENALTY PROCEEDINGS FOR 32.6 MILLION RUPEES DROPPED

Source text: ID:nBSE27YvXm

Further company coverage: SYNN.NS

(([email protected];;))

Corrects paragraph 14 to say India has "committed" not "invested" $2.86 billion

By Rishika Sadam, Kashish Tandon and Bhanvi Satija

HYDERABAD Feb 27 (Reuters) - India's contract drug makers have urged the government to remove regulatory hurdles and grant faster clearance to vital raw material imports at a time when many global pharmaceutical firms are counting on the nation to reduce their reliance on China.

India's Contract Research Development and Manufacturing Organisation (CRDMO) sector is at an inflection point, with the potential to grow seven-fold to $22 billion-$25 billion by 2035, according to a report by Boston Consulting Group.

Globally, the market stands at $140 billion-$145 billion.

"The government has to understand that this industry has potential, if not scale, right now," Krishna Kanumuri, CEO and managing director at Sai Life Sciences SAIE.NS, said at an event earlier this week.

India's contract drug manufacturers have gained from global companies' efforts to diversify their supply chain after the pandemic and a U.S. bill that would prohibit federal contracts with certain Chinese biotech firms on national security grounds.

However, India's policies are yet to play catch-up.

For instance, prolonged approval times and regulatory demands tied to certain raw material imports meant Indian firms often require eight to 15 days to initiate projects, while their Chinese peers could do it within three days, according to Vikash Aggarwala, MD and Partner at BCG's healthcare practice.

Industry insiders pushed for more business-friendly policies in the world's fifth-largest economy, which is heavily dependent on China for drug-related raw materials.

Piramal Pharma's PIRM.NS Chairperson Nandini Piramal lamented the lack of customs warehouses at the right locations and related logistics costs, a dearth of cold storage units, and delays tied to the clearance of certain raw material imports.

"All of those, I think, add more friction to the ease of doing business," Piramal told Reuters.

Some others highlighted the delay in approvals due to the lack of a centralized, digital, single-window clearance system.

Syngene's SYNN.NS CEO-designate Peter Bains said the "friction and delay" could be compressed, highlighting it was "a disadvantage that India has against other jurisdictions".

India's health and finance ministries did not respond to Reuters requests seeking comment.

The country, which offers cheap labour and a large talent pool, has already committed over $2.86 billion in the local biotech industry, according to the BCG report. But industry insiders are urging for more.

"I would really pitch for a CRDMO park... with policies where you don't have to go and get permissions from the local drug controller for making changes, where there are easy export and import capabilities," Aragen Life Sciences CEO Manni Kantipudi said.

($1 = 87.3900 Indian rupees)

(Reporting by Rishika Sadam, Kashish Tandon and Bhanvi Satija; Editing by Dhanya Skariachan and Janane Venkatraman)

(([email protected]; 8800437922;))

Feb 26 (Reuters) - Syngene International Ltd SYNN.NS:

• SYNGENE INTERNATIONAL - TAX DEMAND ORDER REDUCED TO 102 MILLION RUPEES

Source text: ID:nNSEbX1r3H

Further company coverage: SYNN.NS

(([email protected];;))

Feb 10 (Reuters) - Syngene International Ltd SYNN.NS:

• JONATHAN HUNT STEPS DOWN AS MD & CEO OF SYNGENE

• PETER BAINS APPOINTED CEO DESIGNATE OF SYNGENE

Source text: ID:nBSExY3mS

Further company coverage: SYNN.NS

(([email protected];;))

BENGALURU, Jan 23 (Reuters) - Diary of India economic, corporate events on Jan. 23

ECONOMIC, CORPORATE .BSE500 EVENTS:

NTS - 'No time scheduled', AMC - 'After market close'

(Compiled by Bengaluru Newsroom)

(([email protected]))

Jan 14 (Reuters) - Syngene International Ltd SYNN.NS:

• AGGREGATE TAX AMOUNT UNDER GOVERNMENT SCHEME TO BE PAID IS 94.7 MILLION RUPEES

• PAID 15.3 MILLION RUPEES TAX UNDER PROTEST, BALANCE TO BE PAID WITHIN 15 DAYS

Source text: ID:nBSE4gwqJ2

Further company coverage: SYNN.NS

(([email protected];;))

Adds details paragraph 2 onwards

Dec 31 (Reuters) - Indian contract drugmaker Anthem Biosciences filed for a 33.95-billion-rupee ($397 million) initial public offering, draft papers showed on Tuesday, at the fag end of what has been a red-hot year for companies listing on the stock market.

Anthem, whose services include early-stage drug discovery and drug efficacy testing, said private equity firm True North and drugmaker DavosPharma are among investors who will sell shares in the IPO.

The company will not sell any shares and it did not give any other details on the offering.

The Indian IPO market has been bustling this year, with over 300 companies having raised $17.5 billion as of mid-December, more than double the amount raised last year, LSEG data showed.

That gives it the top spot globally in terms of proceeds and volumes, according to consultancy firm KPMG.

Anthem, which began operations in 2007 and has two manufacturing facilities, is also going public at a time when global drugmakers are turning to India and other markets to limit their reliance on Chinese contractors.

Begaluru-based Anthem also makes active pharmaceutical ingredients (API), which are the main component of a drug, as well as dietary supplements and probiotics.

It competes with the likes of Syngene International SYNN.NS, Divi's Laboratories DIVI.NS and newly-listed Sai Life Sciences SAIE.NS among Indian API makers.

($1 = 85.5720 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru; Editing by Savio D'Souza)

(([email protected]; 8800437922;))

** Shares of contract research firm Syngene International SYNN.NS rise as much as 3.5% to 898 rupees

** Biopharma firm Biocon BION.NS is likely to sell 2% stake in Syngene International via block deals, CNBC-TV18 reports citing sources

** Shares of Biocon are nearly flat

** SYNN has been above its 200-day SMA since July

** About 2 mln SYNN shares traded, 2.3x its 30-day moving avg

** Avg rating of eight analysts covering the stock is "hold" and median PT is 820.5 rupees, ~6.5% lower than current price - LSEG data

** SYNN last up 1.2%, extending YTD gains to ~25%

(Reporting by Anuran Sadhu in Bengaluru)

(([email protected]; +91 8697274436;))

Dec 5 (Reuters) - Syngene International Ltd SYNN.NS:

• GOT ORDER MODIFYING TAX DEMAND TO 25.9 MILLION RUPEES

Source text: ID:nNSE63Zmnn

Further company coverage: SYNN.NS

(([email protected];;))

Oct 23 (Reuters) - Syngene International Ltd SYNN.NS:

• RESIGNATION OF CFO SIBAJI BISWAS

• RESIGNATION OF SIBAJI BISWAS, EXECUTIVE DIRECTOR AND CFO

• APPOINTMENT OF DEEPAK JAIN AS CHIEF FINANCIAL OFFICER

• SEPT-QUARTER CONSOL PROFIT 1.06 BILLION RUPEES

• SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 8.91 BILLION RUPEES

Source text for Eikon: ID:nNSE26tD5y

Further company coverage: SYNN.NS

(([email protected];;))

Oct 1 (Reuters) - Syngene International Ltd SYNN.NS:

• GOT TAX REFUND ORDER FOR 136 MILLION RUPEES

Source text for Eikon: ID:nNSEbddVlK

Further company coverage: SYNN.NS

(([email protected];))